Indeed, though our data suggest that HERC1 plausibly plays a role as oncosuppressor in the majority of myeloid malignancies (e.g., AML, CML and PMF) by now we cannot rule out that in those ET calreticulin mutated it might display tumor-promoting properties, thus exerting different properties depending on the context. Here, CALR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.